Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$121.13 +1.67%

+$1.50 today

Market cap
$10.34B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.68M

Average 0.58M

KYMR Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Kymera Therapeutics, Inc.NASDAQ: KYMR

Short-term Investments · Q2 FY2026 · quarter ended Jun 2026

Short-term investments rises 71.9% from a year ago

Short-term investments stood at $566.51M at the end of Q2 FY2026, up 71.9% from a year earlier and up 11.8% from the prior quarter. Over 3 fiscal years it compounded at +13.2% a year.

Context

  • Short-term investments amounted to 34.4% of total assets at the end of Q2 FY2026, up 5.3 pp from a year earlier.
  • Short-term investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term investments keeps rising in the next quarterly balance sheet after a +71.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$566.51M+11.8% QoQ
Last fiscal yearDec 2025
$491.27M+33.3% YoY
Year agoJun 2025
$329.63M+71.9% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+71.9%——
1 year+33.3%——
3-year CAGR+13.2%——
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
491.27M USD
Year-over-year change
+33.3%
4-year CAGR
+5.6%

Short-term Investments vs competitors

How KYMR compares with its peers on the latest reported figures

  • KYMR's Jun 2026 short-term investments of $566.51M is the highest of the 5 companies compared; the peer median is $417.19M.
  • Its year-over-year change of +71.9% is the 2nd highest of 5, against a peer median of +0.0%.
  • Short-term investments amounts to 34.4% of total assets for KYMR, versus a peer median of 60.9%.
KYMR Competitors Peer median
Short-term Investments for KYMR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KYMRKymera Therapeutics, Inc.Jun 2026$566.51M +71.9%+13.2%34.4%
ARVNArvinas, Inc.Mar 2026$527.6M -39.6%-21.6%81.5%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$506.36M +104.6%+5.9%68.8%
NRIXNurix Therapeutics, Inc.Aug 2026$328.01M -6.4%+12.2%27.4%
CCCCC4 Therapeutics, Inc.Mar 2026$174.4M +6.5%-11.0%53.0%
Peer median (excluding KYMR) $417.19M+0.0%-2.5%60.9%

Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents47.98M68.4M109.97M120.26M357.01M
Short-term Investments394.44M338.77M264.92M368.49M491.27M
Net Receivables135K2.54M18.76M947K0
Inventory00000
Other Current Assets09.71M11.67M20.58M22.94M
Total Current Assets451.27M419.42M405.32M510.27M871.21M
Property, Plant & Equipment (Net)21.31M22.24M101.08M97.86M85.53M
Goodwill00000
Intangible Assets00000
Long-term Investments125.19M152.33M61.43M362.16M776.96M
Tax Assets00000
Other Non-current Assets8.14M9.15M7.93M7.74M9.11M
Total Non-current Assets154.63M183.72M170.44M467.77M871.6M
Total Assets605.91M603.13M575.76M978.04M1.74B
Account Payables4.01M4.34M7.08M5.99M4.01M
Short-term Debt000013.76M
Tax Payables00000
Deferred Revenue61.74M35.26M37.88M13.58M22.93M
Other Current Liabilities228K303K23.16M223K24.21M
Total Current Liabilities92.54M71.34M85.69M67.77M83.21M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)39.3M28M16.77M011.44M
Other Non-current Liabilities66K248K000
Total Non-current Liabilities53.73M41.64M95.1M74.65M79.94M
Total Liabilities146.27M112.98M180.79M142.42M163.15M
Common Stock5K6K6K7K8K
Retained Earnings(228.98M)(383.79M)(530.75M)(754.61M)(1.07B)
Accumulated OCI(660K)(4.95M)(552K)(1.49M)1.8M
Other Stockholders Equity00000
Minority Interest00000
Total Equity459.64M490.15M394.97M835.62M1.58B
Total Debt17.96M17.34M84.67M87.76M82.25M
Net Debt(30.01M)(51.06M)(25.29M)(32.5M)(274.76M)

Kymera Therapeutics, Inc.

NASDAQ:KYMR

Intrinsic Alpha fair value

Locked

Current Price

$121.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.